Abstract:SCLC is an aggressive cancer of neuroendocrine origin, accounting for approximately 15% of all lung cancer cases. While the incidence of SCLC in the US has declined over past decades due to changes in smoking habits, this disease provides a poor prognosis and few effective treatment options for advanced disease. To better identify useful therapies for SCLC, we established and characterized a panel of 18 XPDX models representing primary and metastatic disease from either naïve or clinically treated patients and tested sensitivities towards chemotherapies and targeted agents. 18 models were established in immune-deficient mice including 8 from newly diagnosed patients (2 from lung primary), and 10 from recurrent disease (3 from lung primary). Models were IHC stained for Nectin-4, Trop2 protein and ERBB2 and profiled using WES and RNAseq. For in vivo studies, models were evaluated against several chemotherapies including cisplatin, etoposide, topotecan, and temozolomide, as well as ADC agents trastuzumab deruxtecan (T-DXd), enfortumab vedotin (EV), and sacituzumab govitecan (SG). Targeted therapies toward CDK4/6, KRASG12C, and PARP were evaluated in some models. Endpoints in all studies included tumor volume and time from treatment initiation with %T/C values and tumor regression reported at study completion; a %T/C of ≤ 20% versus control was considered sensitive. Tumor regression (%T/C<0%) versus Day 0 tumor volume was also reported. Less than 10% of models stained positive for Nectin-4, Trop-2 or ERBB2. Molecular characterization revealed RB1 frameshifts or deletions in most models, KRAS/NRAS point mutations in 3 models, and 2 gene fusions SEPTIN7P2-PSPH and TVP23C-CDRT4. In vivo studies reported differential responses to chemotherapies with the most sensitive models established from treatment-naïve patients. Temozolomide was active in several studies including tumor regressions in both naïve and pretreated models. ADCs also reported differential activity toward the tested panel. We have established and characterized a panel of SCLC XPDX models and benchmarked them against various cancer therapies. This panel can be utilized as a valuable tool in developing novel therapies for SCLC patients. Citation Format: Gabriela Huelgas Morales, Peter Forofontov, Johnnie Flores, Alyssa Simonson, Armando Diaz III, Jim Lund, Natalia Banos, Kyriakos Papadopoulos, Drew Rasco, Amita Patnaik, Ali Abedi, Napoleon Puente, Emiliano Calvo, Victor Moreno, Ronald Drengler, Lon Smith, Michael Wick. Establishment and characterization of a panel of naïve and pretreated small cell lung cancer (SCLC) XPDX models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6891.

Supplementary Methods from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Figures S7 - S9 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Methods and References from MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial–Mesenchymal Transition and Metastasis in Colorectal Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Supplementary Methods from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Materials and Methods from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Methods from BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

Supplementary Figure 6 from Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice

Supplementary Methods from AZ1366: an Inhibitor of Tankyrase and the Canonical Wnt Pathway That Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition

Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Supplementary materials and methods from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy

Supplementary Experimental Procedures, Supplementary Figure Legends, and Supplementary Tables 1 through 3 from c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers

Supplementary Methods, Figure Legends from Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Supplementary Methods, Figures S1-14 from Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

Abstract 6891: Establishment and characterization of a panel of naïve and pretreated small cell lung cancer (SCLC) XPDX models

Supplementary Figure Legend from Superior Efficacy of a Combined Epigenetic Therapy Against Human Mantle Cell Lymphoma Cells